| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Revenue | 19,474 | 53,644* | 38,837 | |
| Cost of revenue-Service | NaN | 7,880* | NaN | |
| Cost of biosecurity revenue-Biosecurity | NaN | NaN | 8,177 | |
| Cost of revenue-Product | NaN | 0* | NaN | |
| Cost of biosecurity revenue-Other Revenue | NaN | NaN | 4,625 | |
| Cost of revenue-Product And Service Other | NaN | 3,863* | NaN | |
| Cost of other revenue | 3,098 | NaN | NaN | |
| Research and development | 49,920 | 35,714* | 69,353 | |
| General and administrative | 37,830 | 43,537* | 44,954 | |
| Impairment of lease assets | NaN | 0* | NaN | |
| Goodwill impairment | NaN | 0* | 0 | |
| Restructuring charges | 0 | 6,163* | 1,745 | |
| Total operating expenses | 90,848 | 97,157* | 128,854 | |
| Loss from operations | -71,374 | -43,513* | -90,017 | |
| Interest income | NaN | 5,654* | NaN | |
| Interest expense | NaN | 0* | NaN | |
| Loss on equity method investments | NaN | 0* | NaN | |
| Interest income, net | 3,596 | NaN | 5,742 | |
| Loss on investments | -1,214 | -27,727* | 3,684 | |
| Loss on deconsolidation of subsidiary | NaN | NaN | 0 | |
| Loss on deconsolidation of subsidiaries | NaN | 0* | NaN | |
| Change in fair value of warrant liabilities | NaN | 0* | 0 | |
| Other expense, net | -7,147 | -4,038* | -163 | |
| Total other expense | -4,765 | -26,111* | 9,263 | |
| Loss from continuing operations before income taxes | -76,139 | -69,624* | -80,754 | |
| Income tax (benefit) expense | -80 | -840* | 1 | |
| Net loss from continuing operations | -76,059 | NaN | NaN | |
| Net loss from discontinued operations, net of tax | -6,528 | NaN | NaN | |
| Net loss | -82,587 | -68,784* | -80,755 | |
| Foreign currency translation adjustment | -579 | 883* | 27 | |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | NaN | 0* | 0 | |
| Unrealized gain on available-for-sale securities | NaN | -31* | NaN | |
| Unrealized gains (loss) on available-for-sale securities | -78 | NaN | 316 | |
| Total other comprehensive income (loss) | NaN | 914* | NaN | |
| Total other comprehensive (loss) income | -657 | NaN | 343 | |
| Comprehensive loss | -83,244 | -67,870 | -80,412 | |
| Basic EPS | -1.39 | -1.228 | -1.45 | |
| Diluted EPS | NaN | -1.228 | -1.45 | |
| Basic Average Shares | 59,563,454 | 55,281,634 | 55,633,718 | |
| Diluted Average Shares | NaN | 55,281,634 | 55,633,718 | |
Ginkgo Bioworks Holdings, Inc. (DNABW)
Ginkgo Bioworks Holdings, Inc. (DNABW)